Day One Biopharmaceuticals Sees Stock Decline Amid Acquisition Risks

Day One Biopharmaceuticals shares are trading lower after announcing a merger agreement to acquire Mersana Therapeutics, with concerns over integration risks and future milestone achievements impacting investor confidence.